RAP-219

Phase 2Recruiting
2 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bipolar 1 Disorder

Conditions

Bipolar 1 Disorder

Trial Timeline

Jul 25, 2025 → Dec 1, 2026

About RAP-219

RAP-219 is a phase 2 stage product being developed by Rapport Therapeutics for Bipolar 1 Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07046494. Target conditions include Bipolar 1 Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Bipolar 1 Disorder were approved

Approved (20) Terminated (3) Active (0)
Olanzapine + PlaceboEli LillyApproved
OlanzapineEli LillyApproved
OlanzapineEli LillyApproved
olanzapine + risperidoneEli LillyApproved
Topiramate + PlaceboEli LillyApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT07219407Phase 2Recruiting
NCT07046494Phase 2Recruiting
NCT06377930Phase 2Completed

Competing Products

20 competing products in Bipolar 1 Disorder

See all competitors
ProductCompanyStageHype Score
OlanzapineEli LillyPhase 3
32
Valproate + Lithium + Risperidone + OlanzapineEli LillyPhase 3
40
Olanzapine + PlaceboEli LillyApproved
43
FK949EAstellas PharmaPhase 3
40
FK949EAstellas PharmaPhase 3
40
FK949E + PlaceboAstellas PharmaPhase 2/3
38
Escitalopram + Bupropion XLLupin LimitedPhase 3
32
OlanzapineEli LillyApproved
43
Olanzapine Hydrochloride + Lithium CarbonateEli LillyPhase 3
40
olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
40
OlanzapineEli LillyApproved
43
OlanzapineEli LillyPhase 3
40
LY2979165 + PlaceboEli LillyPhase 1
29
olanzapine + divalproex sodium + placeboEli LillyApproved
43
olanzapine + risperidoneEli LillyApproved
43
LY2979165 + placeboEli LillyPhase 1
29
Topiramate + PlaceboEli LillyApproved
43
olanzapineEli LillyPhase 3
40
Olanzapine + PlaceboEli LillyPhase 3
40
Brenipatide + PlaceboEli LillyPhase 2
42